Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database
| dc.rights.license | open | en_US |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | DI NAPOLI, Raffaella | |
| hal.structure.identifier | Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept] | |
| dc.contributor.author | RICHEZ, Christophe | |
| dc.contributor.author | SCAVONE, Cristina | |
| dc.contributor.author | SINGIER, Allison | |
| dc.contributor.author | DEMORGUES, Maxime | |
| dc.contributor.author | MASCOLO, Annamaria | |
| dc.contributor.author | CAPUANO, Annalisa | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | SALVO, Francesco
IDREF: 221043470 | |
| dc.date.accessioned | 2025-04-18T09:26:57Z | |
| dc.date.available | 2025-04-18T09:26:57Z | |
| dc.date.issued | 2025-03-23 | |
| dc.identifier.issn | 0114-5916 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/206294 | |
| dc.description.abstractEn | BACKGROUND: Rheumatoid arthritis (RA) is commonly treated with Janus kinase inhibitors (JAKis) and anti-tumor necrosis factor-α (anti-TNFα), but the cardiovascular safety profiles of these drugs remain unclear. OBJECTIVE: The aim of this study was to describe the individual case safety reports of major adverse cardiac events (MACE) or stroke and to determine whether there was a difference in the frequency of reporting of cardiovascular events between JAKis and anti-TNFα used in RA. METHODS: A case/non-case study was conducted using the WHO VigiBase(®) database. Descriptive analysis was performed, the time to onset (TTO) of MACE was calculated, and the reporting odds ratio (ROR) was used to estimate the frequency of MACE reports associated with JAKis versus anti-TNFα in RA. RESULTS: A total of 18,099 cases of MACE were identified, of which 2543 (14%) were associated with JAKis, predominantly in women (65.4%) and in patients aged ≥65 years (49.9%). The median time to onset was 210 days (IQR 60-510) for JAKis and 690 days (210-1460) for anti-TNFα. JAKis were associated with higher odds of reporting MACE (ROR 1.38 [95% CI 1.32-1.44]), mainly due to non-fatal stroke (1.65 [1.55-1.75]). Stroke as a whole showed similar results (1.62 [1.53-1.72]). The ROR of MACE was also slightly increased in patients aged <65 years treated with JAKis (1.29 [1.21-1.39]). CONCLUSIONS: Compared with anti-TNFα, JAKis were more associated with MACE, especially stroke, and with a shorter time to onset. These data support the hypothesis of a different cardiovascular reporting frequency between JAKis and anti-TNFα. In patients with identified cardiovascular risk, anti-TNFα should be preferred to JAKis until more definitive results are available. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/us/ | * |
| dc.title.en | Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database | |
| dc.title.alternative | Drug Saf | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1007/s40264-025-01535-8 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 40121611 | en_US |
| bordeaux.journal | Drug Safety | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.institution | CNRS | |
| bordeaux.team | AHEAD_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-05039380 | |
| hal.version | 1 | |
| hal.date.transferred | 2025-04-18T09:27:00Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Drug%20Safety&rft.date=2025-03-23&rft.eissn=0114-5916&rft.issn=0114-5916&rft.au=DI%20NAPOLI,%20Raffaella&RICHEZ,%20Christophe&SCAVONE,%20Cristina&SINGIER,%20Allison&DEMORGUES,%20Maxime&rft.genre=article |